Saffron may be a promising herbal alternative for treating ADHD

NewsGuard 100/100 Score

A new short-term pilot study in children and teens 6-17 years old with attention-deficit hyperactivity disorder (ADHD) has shown saffron to be as effective at controlling symptoms as methylphenidate, the commonly prescribed drug Ritalin. Saffron may be a promising herbal alternative for treating ADHD, particularly for the 30% of patients who do not respond to or cannot tolerate stimulants like methylphenidate, as reported in an article published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

The article entitled "Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study" was coauthored by Sara Baziar, MD, Ali Aqamolaei, MD and colleagues from Tehran University of Medical Sciences, Iran. The researchers note that saffron also has anti-depressant and memory-enhancing properties. They compared the effects of Crocus sativus L. to methylphenidate in 54 patients over a 6-week period and showed no significant difference in effectiveness as well as similar frequency of adverse effects.

"This is a very interesting study and an intriguing finding. It is worthy of replication and further study to understand the mechanism of action," says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AVAnT1A study: Investigating early COVID-19 vaccination and type 1 diabetes risk in children